Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Subject- and Investigator-Blind, Placebo and Active-Controlled Study to Assess the Abuse Potential of Lasmiditan

NCT03286218 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03286218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03286218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Subject- and Investigator-Blind, Placebo and Active-Controlled Study to Assess the Abuse Potential of Lasmiditan
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
September 15, 2017
Completion date
November 20, 2017
Enrollment
96 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prescription drug abuse (not dependent), recreational drug use